Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 37.50.
Forward PE Ratio (37.50) = Close Price ($72.15) / Consensus Forward EPS ($1.92)
FORWARD PE RATIO
37.50
SECTOR MEDIAN · HEALTHCARE
20.09
median of 67 covered companies
CURRENT VS SECTOR MEDIAN
+86.66%
vs the sector median at left
Bio-Techne Corporation
Market Cap
$11.30B
Forward PE Ratio
37.50
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bio-Techne Corporation (TECH) | $11.30B | 37.50 |
| DaVita Inc. (DVA)vs › | $11.45B | 12.42 |
| Universal Health Services, Inc. (UHS)vs › | $10.21B | 7.63 |
| Align Technology, Inc. (ALGN)vs › | $12.39B | 15.61 |
| Henry Schein, Inc. (HSIC)vs › | $10.16B | 16.37 |
| Molina Healthcare, Inc. (MOH)vs › | $10.15B | N/A |
| Insulet Corp. (PODD)vs › | $10.02B | 21.93 |
| Tempus AI, Inc. (TEM)vs › | $9.76B | N/A |
| Revvity, Inc. (RVTY)vs › | $12.91B | 21.66 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.59B | 36.77 |
Trailing P/E
104.5
reported TTM EPS
Forward P/E
37.5
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.92 implies +178.3% EPS growth vs the reported trailing $0.69.
At today's $72.15 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $2.05 | $1.95 – $2.16 | 7 | 35.2x |
| 2028-06-30 | $2.32 | $2.17 – $2.49 | 3 | 31.1x |
| 2029-06-30 | $2.67 | $2.59 – $2.78 | 1 | 27.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
